- Home
- RCKT vs MAZE Comparison
RCKT vs MAZE Comparison
Compare RCKT & MAZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKT
- MAZE
- Stock Information
- Founded
- RCKT 1999
- MAZE 2018
- Country
- RCKT United States
- MAZE United States
- Employees
- RCKT N/A
- MAZE N/A
- Industry
- RCKT Biotechnology: Pharmaceutical Preparations
- MAZE
- Sector
- RCKT Health Care
- MAZE
- Exchange
- RCKT Nasdaq
- MAZE NYSE
- Market Cap
- RCKT 326.4M
- MAZE 367.0M
- IPO Year
- RCKT N/A
- MAZE 2025
- Fundamental
- Price
- RCKT $2.70
- MAZE $11.18
- Analyst Decision
- RCKT Buy
- MAZE Strong Buy
- Analyst Count
- RCKT 13
- MAZE 3
- Target Price
- RCKT $18.50
- MAZE $25.67
- AVG Volume (30 Days)
- RCKT 8.4M
- MAZE 96.1K
- Earning Date
- RCKT 08-04-2025
- MAZE 08-14-2025
- Dividend Yield
- RCKT N/A
- MAZE N/A
- EPS Growth
- RCKT N/A
- MAZE N/A
- EPS
- RCKT N/A
- MAZE 0.34
- Revenue
- RCKT N/A
- MAZE $167,500,000.00
- Revenue This Year
- RCKT N/A
- MAZE N/A
- Revenue Next Year
- RCKT N/A
- MAZE N/A
- P/E Ratio
- RCKT N/A
- MAZE $33.33
- Revenue Growth
- RCKT N/A
- MAZE N/A
- 52 Week Low
- RCKT $2.19
- MAZE $6.71
- 52 Week High
- RCKT $26.98
- MAZE $17.00
- Technical
- Relative Strength Index (RSI)
- RCKT 32.09
- MAZE N/A
- Support Level
- RCKT $2.66
- MAZE N/A
- Resistance Level
- RCKT $3.33
- MAZE N/A
- Average True Range (ATR)
- RCKT 0.28
- MAZE 0.00
- MACD
- RCKT 0.09
- MAZE 0.00
- Stochastic Oscillator
- RCKT 26.59
- MAZE 0.00
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.